Drugs News and Research

RSS

Novel organoid models illuminate path to cervical cancers

How do tumors develop in the cervix? Many new details are now known about this question. This is also thanks to Dr. Cindrilla Chumduri from the Biocentre at the University of Würzburg.

18 Jan 2021

Two common blood pressure drugs are not tied to increased risk of COVID-19

Research published in the peer-reviewed journal The Lancet Digital Health and co-led by a UCLA Fielding School of Public Health faculty member has found that two widely used types of blood pressure drugs are not tied to an increased risk of COVID-19 infection or complications.

18 Jan 2021

Study finds new evidence about the positive role of androgens in breast cancer treatment

Researchers at the University of Adelaide have found new evidence about the positive role of androgens in breast cancer treatment with immediate implications for women with estrogen receptor-driven metastatic disease.

18 Jan 2021

Modified natural killer cells show neutralizing and multivalent potential against SARS-CoV-2 in vitro

A new study suggests that modified natural killer cells, which express a chimeric antigen receptor using S309 antibody, can bind to and inactivate SARS-CoV-2 spike protein in vitro.

18 Jan 2021

Personalized neuromodulation approach provides relief from severe depression symptoms

Targeted neuromodulation tailored to individual patients' distinctive symptoms is an increasingly common way of correcting misfiring brain circuits in people with epilepsy or Parkinson's disease.

18 Jan 2021

Angiopoietin-2 is a crucial determinant of COVID-19 prognosis, study finds

A team of scientists from the United States and Sweden has recently demonstrated that increased levels of a proinflammatory cytokine, angiopoietin-2, is responsible for hypercoagulation observed in severe COVID-19 patients.

18 Jan 2021

Can transgenic mice studies illuminate neurological complications associated with SARS-CoV-2 in humans?

The potentially deadly COVID-19 has not affected animals with corresponding severity. To understand the mechanism of severe disease, animal models have been used. This includes a mouse model that expresses human angiotensin-converting enzyme 2 (hACE2) under the cytokeratin 18 promoter (K18-hACE2). A new study indicates that this may not be a faithful model of human lethal infection with SARS-CoV-2.

18 Jan 2021

Study reveals new way to target cancer’s nutritional needs

Scientists discover a way to target cancer’s nutritional needs, which could lead to a new way to treat the disease, according to a study published in Nature Communications today (Thursday).

18 Jan 2021

Study: Fibroblast hormone promotes movement of hematopoietic stem cells

Discovery expected to contribute towards more effective methods of harvesting stem cells from bone marrow donors.

17 Jan 2021

Researchers design new biosynthetic pathways for short-chain primary amines

Researchers report a new strategy for the microbial production of multiple short-chain primary amines via retrobiosynthesis.

17 Jan 2021

FDA issues warning letters to firms selling e-liquids which lack premarket authorization

Today, the U.S. Food and Drug Administration issued warning letters to 10 firms who manufacture and operate websites selling electronic nicotine delivery system (ENDS) products, specifically e-liquids, advising them that selling these products, which lack premarket authorization, is illegal, and therefore they cannot be sold or distributed in the U.S.

17 Jan 2021

New nasal spray delivers antipsychotic medication directly to the brain

A team of neuroscientists and engineers at McMaster University has created a nasal spray to deliver antipsychotic medication directly to the brain instead of having it pass through the body.

16 Jan 2021

Experts release newly-established principles of care for young adults with substance use disorder

A national group of pediatric addiction medicine experts have released newly-established principles of care for young adults with substance use disorder.

16 Jan 2021

Combination therapy reduces recovery time in COVID-19 patients, clinical trial finds

A clinical trial involving COVID-19 patients hospitalized at UT Health San Antonio and University Health, among roughly 100 sites globally, found that a combination of the drugs baricitinib and remdesivir reduced time to recovery, according to results published Dec. 11 in the New England Journal of Medicine.

16 Jan 2021

Study: NTRK fusions are far more frequently seen in pediatric tumors

In a large study of pediatric cancer patients, researchers from Children's Hospital of Philadelphia have analyzed the frequency, fusion partners, and clinical outcome of neurotrophic tyrosine receptor kinase (NTRK) fusions, which are clinical biomarkers that identify patients suitable for treatment with FDA-approved TRK inhibitors.

16 Jan 2021

New antiviral repurposing study finds peptides that could prevent SARS-CoV-2-ACE2 binding

A new study reports the antiviral potential of peptides against SARS-CoV-2's spike protein.

15 Jan 2021

Study reports promising new monoclonal antibody against SARS-CoV-2’s spike protein

An encouraging new study describes a promising new therapeutic antibody that shows potent neutralizing activity against SARS-CoV-2, the causative agent of COVID-19.

15 Jan 2021

Study shows why antihistamine drugs fail to control severe itch in eczema patients

In addition to a skin rash, many eczema sufferers also experience chronic itching, but sometimes that itching can become torturous. Worse, antihistamines -- the standard treatment for itching and allergy -- often don't help.

15 Jan 2021

Study may lead to novel synthetic drugs to combat bacterial infections

Researchers at the Technion – Israel Institute of Technology and EMBL Hamburg have discovered remarkable molecular properties of an antimicrobial peptide from the skin of the Australian toadlet. The discovery could inspire the development of novel synthetic drugs to combat bacterial infections.

15 Jan 2021

New drug reduces tumor volume and pain in patients with neurofibromatosis type 1

Based on preclinical studies of an investigational drug to treat peripheral nerve tumors, researchers at Children's Hospital of Philadelphia (CHOP) as part of the Neurofibromatosis Clinical Trials Consortium have shown that the drug, cabozantinib, reduces tumor volume and pain in patients with the genetic disorder neurofibromatosis type 1 (NF1).

15 Jan 2021

Drugs News and Research

Novel organoid models illuminate path to cervical cancers

Two common blood pressure drugs are not tied to increased risk of COVID-19

Study finds new evidence about the positive role of androgens in breast cancer treatment

Modified natural killer cells show neutralizing and multivalent potential against SARS-CoV-2 in vitro

Personalized neuromodulation approach provides relief from severe depression symptoms

Angiopoietin-2 is a crucial determinant of COVID-19 prognosis, study finds

Can transgenic mice studies illuminate neurological complications associated with SARS-CoV-2 in humans?

Study reveals new way to target cancer’s nutritional needs

Study: Fibroblast hormone promotes movement of hematopoietic stem cells

Researchers design new biosynthetic pathways for short-chain primary amines

FDA issues warning letters to firms selling e-liquids which lack premarket authorization

New nasal spray delivers antipsychotic medication directly to the brain

Experts release newly-established principles of care for young adults with substance use disorder

Combination therapy reduces recovery time in COVID-19 patients, clinical trial finds

Study: NTRK fusions are far more frequently seen in pediatric tumors

New antiviral repurposing study finds peptides that could prevent SARS-CoV-2-ACE2 binding

Study reports promising new monoclonal antibody against SARS-CoV-2’s spike protein

Study shows why antihistamine drugs fail to control severe itch in eczema patients

Study may lead to novel synthetic drugs to combat bacterial infections

New drug reduces tumor volume and pain in patients with neurofibromatosis type 1

Event guide: 4th Extra-Hepatic Lipid-Based Nanoparticles Delivery Summit eBook

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo

Latest News